Akcea and Ionis Complete Licensing Transaction to Commercialize Inotersen for hATTR

Akcea Therapeutics (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals and Ionis Pharmaceuticals (NASDAQ:IONS) announced the two companies have completed a previously announced transaction licensing the exclusive, worldwide rights from Ionis to Akcea for inotersen and AKCEA-TTR-L_Rx, formerly IONIS-TTR-L_Rx.

As quoted in the press release:

Inotersen is under regulatory review in the U.S. and EU with approvals planned for mid-2018 for the treatment of hereditary transthyretin amyloidosis, or hATTR. hATTR is a systemic, progressive and fatal disease. Akcea and Ionis are also developing AKCEA-TTR-L_Rx for hereditary and wild-type forms of ATTR and plan to commence clinical studies for AKCEA-TTR-L_R in 2018.

In addition, following the close of the transaction, today, Sarah Boyce joined Akcea as president and a member of the Akcea board of directors reporting to Paula Soteropoulos, Akcea’s chief executive officer. Ms. Boyce was formerly the chief business officer at Ionis.

Click here to read the full press release.